GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Viatris Inc.
Viatris, created through the merger of Mylan and Upjohn (a division of Pfizer), is a global manufacturer of generic and branded drugs that have lost patent protection. Its share price reflects price pressure in the generics sector and the company's efforts to find new sources of growth.
Share prices of companies in the market segment - Pharma holding
Viatris is a global manufacturer of generic and branded drugs that have lost patent protection. We classify it as a pharmaceutical holding company. The chart below shows the overall dynamics of this sector, characterized by pricing pressure and the search for new sources of growth.
Broad Market Index - GURU.Markets
Viatris is a global pharmaceutical company created by the merger of Mylan and Upjohn, producing a wide range of generic and branded medications. Its market capitalization earns it a spot in the GURU.Markets index. The chart below shows the overall market performance. Compare its stock to the overall healthcare sector.
Change in the price of a company, segment, and market as a whole per day
VTRS - Daily change in the company's share price Viatris Inc.
The daily price change for Viatris, a major generic drug manufacturer, reflects its response to patent news and price competition. While the graph of these fluctuations is unspectacular, it is a critical component of the formulas on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma holding
Viatris Inc. is a global pharmaceutical company created by the merger of Mylan and Upjohn. This chart shows the average daily volatility of the sector. Comparing it with the VTRS dynamics, which focuses on generics and branded drugs that have lost their patents, helps assess its unique risk profile.
Daily change in the price of a broad market stock, index - GURU.Markets
Viatris is a global pharmaceutical company formed from the merger of Mylan and Upjohn (a division of Pfizer). The company specializes in generic and brand-name medications. The chart below shows overall market volatility, providing context for assessing Viatris' strategy.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Viatris Inc.
Viatris, formed by the merger of Mylan and Upjohn, is a giant in the generic and over-the-counter drug market. Its year-over-year performance reflects a complex integration process and its strategy of focusing on the most profitable segments.
Annual dynamics of market capitalization of the market segment - Pharma holding
Viatris Inc., created through the merger of Mylan and Upjohn (a division of Pfizer), is a global manufacturer of generic and branded drugs that have lost patent protection. Its goal is to stabilize revenues and find new sources of growth. The chart will show how successful these efforts are in the complex healthcare sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Viatris is a global pharmaceutical company formed from the merger of Mylan and Upjohn (a division of Pfizer). It specializes in generic and branded off-patent medications. Its dynamics reflect the challenges and opportunities in this market.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Viatris Inc.
The value of Viatris, the global pharmaceutical company formed by the merger of Mylan and Upjohn, depends on its operational transformation. Monthly fluctuations on the chart reflect success in generic drug sales, lifecycle management of established brands (such as Viagra), and efforts to reduce debt and optimize business.
Monthly dynamics of market capitalization of the market segment - Pharma holding
This chart shows the dynamics of the pharmaceutical sector, specifically the generics segment. For Viatris, one of the world's largest manufacturers, this is the backdrop. The chart illustrates how pricing pressure and competition in this segment impact the entire industry.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Viatris is a global pharmaceutical company formed through a merger, focusing on generics and well-known brands. As a member of the healthcare sector, it can be less volatile than the overall market. Amid the general fluctuations shown in the chart, Viatris's story is an attempt to prove the effectiveness of its business model and ensure stable cash flow.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Viatris Inc.
Viatris is a major generic drug manufacturer, and its shares are sensitive to news about patent disputes and new drug approvals. Weekly performance reflects the ongoing battle for market share and investor reactions to regulatory decisions in the pharmaceutical industry.
Weekly dynamics of market capitalization of the market segment - Pharma holding
Viatris is a major generics manufacturer operating in a highly competitive pharmaceutical market. Comparing its weekly performance with the generics sector reveals its market position. The chart shows whether the company's scale and drug portfolio help it stay ahead of its competitors or lag behind them.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Viatris, as a generic drug manufacturer, should demonstrate stability less dependent on economic cycles. Comparing its weekly performance with the broader market will reveal whether this is the case. The chart allows one to assess whether the company's shares are truly a safe haven, less susceptible to general market turmoil.
Market capitalization of the company, segment and market as a whole
VTRS - Market capitalization of the company Viatris Inc.
Viatris's market capitalization chart is a story of its search for a place in the world of generic and branded drugs. Created through a merger, the company's chart reflects the market's attempts to assess its future strategy and ability to generate stable cash flow. Its price dynamics reflect investors' doubts and hopes for the success of this transformation.
VTRS - Share of the company's market capitalization Viatris Inc. within the market segment - Pharma holding
Viatris is a global pharmaceutical company formed from the merger of Mylan and Upjohn (Pfizer). It specializes in the production of generic and branded drugs. Its market share reflects the scale of its manufacturing capacity and global reach. The chart below shows Viatris's market share in affordable medications worldwide.
Market capitalization of the market segment - Pharma holding
Viatris, created by the merger of Mylan and Upjohn, is a giant in the generic and over-the-counter drug market. The chart below shows the overall market capitalization of the pharmaceutical sector. It provides an insight into the scale of the industry, where Viatris is vying for market share using its manufacturing prowess and broad drug portfolio.
Market capitalization of all companies included in a broad market index - GURU.Markets
Here's the price of one of the largest generic drug manufacturers. The Viatris line on the chart doesn't promise explosive growth, but it demonstrates enormous scale and stable demand for affordable medications. This is a visualization of the part of the pharmaceutical industry that provides healthcare worldwide, making it more accessible.
Book value capitalization of the company, segment and market as a whole
VTRS - Book value capitalization of the company Viatris Inc.
Viatris's book value is the sum of its global manufacturing facilities, pharmaceutical patents, and research and development centers. This material and intellectual capital enables the company to produce a vast portfolio of drugs. The chart below shows how this foundation was formed after acquisitions and through asset optimization.
VTRS - Share of the company's book capitalization Viatris Inc. within the market segment - Pharma holding
Viatris is a giant in the pharmaceutical manufacturing world. The company's strength lies in its global network of pharmaceutical plants capable of producing massive volumes of drugs. The chart shows the significant share of the global physical infrastructure for generic and off-patent drug production that Viatris controls.
Market segment balance sheet capitalization - Pharma holding
Viatris, as a major generic drug manufacturer, relies on a global network of factories. Its business is capital-intensive, requiring large-scale production facilities to produce billions of tablets. The BCap_Seg sector chart shows that the entire pharmaceutical industry is an industry with a vast material base.
Book value of all companies included in the broad market index - GURU.Markets
As a pharmaceutical giant, Viatris possesses vast tangible assets: dozens of factories worldwide, research centers, and a complex logistics network. The company's book value is a physical reflection of its manufacturing power. The chart below demonstrates the scale of this global drugmaker.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Viatris Inc.
For Viatris, a giant generic drug manufacturer, the book value of its plants is very high. If the market values the company close to or below this value, it may indicate doubts about future growth and pricing pressure in the industry. The chart reflects investors' confidence in the company's ability to generate revenue from its assets.
Market to book capitalization ratio in a market segment - Pharma holding
Viatris specializes in the production of generics and established, off-patent drugs. Its value lies in its production scale and broad portfolio of drugs. The chart shows how the market values this volume-driven business model, rather than new developments, relative to its assets.
Market to book capitalization ratio for the market as a whole
Viatris is a pharmaceutical company specializing in generic drugs. Its value is determined by its drug portfolio, production capacity, and distribution efficiency. This chart helps investors assess how the company's tangible assets compare to its ability to generate stable cash flow compared to the market.
Debts of the company, segment and market as a whole
VTRS - Company debts Viatris Inc.
Viatris, a global pharmaceutical company formed through a merger, uses debt to manage its extensive drug portfolio. Borrowed funds can be used for restructuring, production optimization, and shareholder distributions. This chart shows how the company balances debt repayment with investments in future growth.
Market segment debts - Pharma holding
Viatris, a global pharmaceutical company formed through mergers, often faces significant debt inherited from such transactions. Managing this debt becomes a key challenge. This chart shows how successfully the company is reducing its debt and what financial policies it is pursuing following a major restructuring.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Viatris Inc.
Viatris, a global pharmaceutical company formed through a merger, manages a large portfolio of drugs. This chart shows its debt-to-equity ratio. Investors should monitor this metric to understand how the company is integrating and optimizing its business after the merger.
Market segment debt to market segment book capitalization - Pharma holding
Viatris, the merger's parent company, operates in the pharmaceutical industry, focusing on generics and well-known brands. Its debt load may be a legacy of previous transactions. The chart shows how the company manages its debt relative to the overall financial structure and size of the pharmaceutical industry.
Debt to book value of all companies in the market
Viatris, a major pharmaceutical company, carries a debt load, possibly a legacy of mergers. This chart allows us to assess whether its debt is significant not only in the pharmaceutical industry but also in the broader economy. It compares the company's debt structure to the total capitalization of the entire stock market.
P/E of the company, segment and market as a whole
P/E - Viatris Inc.
Viatris is a global pharmaceutical company created through the merger of Mylan and Upjohn (a division of Pfizer). It specializes in producing generic and brand-name drugs. This chart shows its market revenue valuation. This metric often reflects challenges and opportunities in the pharmaceutical industry, including patent expirations, competition, and drug launch strategies.
P/E of the market segment - Pharma holding
Viatris is a major generic drug manufacturer operating in a highly competitive price environment. This chart shows the average profit estimate for the pharmaceutical industry. Comparisons with these estimates help understand how the market views Viatris' strategy: whether its low valuation reflects the general challenges of the generics industry or the company's specific difficulties.
P/E of the market as a whole
Viatris is a global pharmaceutical company created by the merger of Mylan and Upjohn (Pfizer), specializing in generics and well-known brands. Its business is characterized by high volumes and affordable prices. This chart reflects the general level of speculative interest. Viatris's valuation often depends not on market euphoria, but on fundamental metrics: cash flow, dividends, and debt management.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Viatris Inc.
Viatris is a global pharmaceutical company formed from the merger of Mylan and Upjohn. This chart reflects analyst expectations regarding the success of the integration and the company's ability to generate stable cash flow from the sale of generic and brand-name drugs with expired patents.
%20P%2FE%20Viatris%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Viatris-Inc.&v=1772513742689 "Chart of the company's future (projected) P/E Viatris Inc.")
Future (projected) P/E of the market segment - Pharma holding
Viatris, created through the merger of Mylan and Upjohn (a division of Pfizer), is a global manufacturer of generic and branded drugs. This chart shows average profitability expectations for the pharmaceutical sector. It helps assess the market's confidence in the synergies and the company's ability to compete in the low-margin generics segment.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20holding&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-holding&v=1772513742689 "Future (projected) P/E graph of the market segment - Pharma holding")
Future (projected) P/E of the market as a whole
Viatris is a global pharmaceutical company created by the merger of Mylan and Upjohn (a division of Pfizer), specializing in generics and brand-name drugs. This chart reflects general market expectations. For Viatris, which operates in the healthcare sector, it helps understand how the market views its stable cash flow against a backdrop of more volatile sectors.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513742691 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Viatris Inc.
Viatris is a global pharmaceutical company formed through a merger, specializing in generic and branded drugs. The performance presented here reflects its ability to integrate assets and compete in the affordable drug market. Profit is driven by sales volume, patent expirations, and manufacturing network efficiency.
Profit of companies in the market segment - Pharma holding
Viatris is a global pharmaceutical company formed from the merger of Mylan and Upjohn (a division of Pfizer). It specializes in the production of generic and branded drugs. This chart reflects the overall profitability of the pharmaceutical sector, where the scale of production and distribution at giants like Viatris plays a crucial role in drug accessibility.
Overall market profit
Viatris is a global pharmaceutical company created by the merger of Mylan and Upjohn. It specializes in the production of generic and branded medications. Its business is less susceptible to economic cycles, as demand for its medications is constant. This ensures a stable contribution to overall corporate profits, as illustrated by this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Viatris Inc.
Viatris is a global pharmaceutical company created by the merger of Mylan and Upjohn (a division of Pfizer). It specializes in generic and brand-name medications. This chart shows analysts' earnings expectations, which depend on the successful integration of the businesses, new product launches, and competition in the generic drug market.
%20profit%20of%20the%20company%20Viatris%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Viatris-Inc.&v=1772513742701 "Graph of future (projected) profit of the company Viatris Inc.")
Future (predicted) profit of companies in the market segment - Pharma holding
Viatris was created through a merger to manage a vast portfolio of well-known generic and over-the-counter drugs, such as Viagra and Lipitor. Its mission is to optimize sales and find new markets. This graph shows the future profitability of the entire pharmaceutical holding, helping to understand how effective Viatris' strategy is relative to the industry as a whole.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20holding&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-holding&v=1772513742702 "Graph of future (predicted) profits of companies in a market segment - Pharma holding")
Future (predicted) profit of the market as a whole
Viatris is a global pharmaceutical company formed through a merger. It specializes in the production of generic and branded medications. The overall economic situation, reflected in this chart, impacts healthcare systems worldwide and the ability of patients and governments to afford medications.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513742703 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Viatris Inc.
Viatris was created through a merger to manage a massive portfolio of well-known, but no longer generic, drugs. This chart illustrates how the market values the generics giant's revenue. The metric reflects the challenges associated with pricing pressure, but also the strength of its scale and distribution reach.
P/S market segment - Pharma holding
Viatris Inc. is a global pharmaceutical company created by the merger of Mylan and Upjohn. It manufactures and markets a wide range of medications, including generics, branded medications, and over-the-counter (OTC) products. This chart reflects the average valuation in the pharmaceutical industry, providing insight into how the market perceives the scale and diversification of Viatris's business through its revenue.
P/S of the market as a whole
Viatris is a global pharmaceutical company formed by the merger of Mylan and Upjohn (a division of Pfizer), specializing in generics and well-known brands. For a company operating in a vast but competitive market, this chart is important. It helps understand how investors evaluate revenue in the healthcare sector, which balances stability with the risk of patent expirations.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Viatris Inc.
Viatris is a global pharmaceutical company formed by the merger of Mylan and Upjohn (Pfizer). It specializes in generics and well-known brands that have lost patent protection. This chart reflects the company's valuation of its future sales, demonstrating how investors perceive its ability to compete in the generic drug market.
%20P%2FS%20Viatris%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Viatris-Inc.&v=1772513742730 "The graph of the company's future (projected) P/S Viatris Inc.")
Future (projected) P/S of the market segment - Pharma holding
Viatris is a global pharmaceutical company formed from the merger of Mylan and Upjohn (a division of Pfizer). It specializes in producing generic and branded drugs. This chart shows how investors estimate its future earnings compared to other major players in the pharmaceutical industry.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20holding&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-holding&v=1772513742732 "Future (projected) P/S market segment graph - Pharma holding")
Future (projected) P/S of the market as a whole
Viatris is a global pharmaceutical company created by the merger of Mylan and Upjohn. Its generic and brand-name drug businesses are less susceptible to economic cycles, as medications are always in demand. This chart for Viatris reflects the general investment environment rather than the direct demand driver, which is determined by patents and the healthcare system.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513742741 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Viatris Inc.
This chart illustrates the scale of the global pharmaceutical market. For Viatris, created by the merger of Mylan and Upjohn, it reflects the combined results of its vast portfolio of drugs, including both well-known brands (such as Lipitor) and numerous generics worldwide.
Sales of companies in the market segment - Pharma holding
Viatris Inc. is a global pharmaceutical company specializing in generic and brand-name drugs. Its sales account for a significant share of the generic drug market. This chart shows how patent expirations on brand-name drugs and price competition in the generic segment affect revenue for Viatris and the industry as a whole.
Overall market sales
Viatris is a global pharmaceutical company created by the merger of Pfizer and Mylan. It produces a wide range of medications, including generics. Its sales reflect the global demand for affordable medicines. This sector is an important and stable component of consumer spending, contributing to the overall economic picture shown in this chart.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Viatris Inc.
Viatris is a global pharmaceutical company created by the merger of Mylan and Upjohn (Pfizer), specializing in the production of generic and brand-name medications. Future sales forecasts reflect competition in the generic drug market and the success of new product launches.
%20sales%20of%20the%20company%20Viatris%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Viatris-Inc.&v=1772513742748 "Schedule of future (projected) sales of the company Viatris Inc.")
Future (projected) sales of companies in the market segment - Pharma holding
Viatris is a global pharmaceutical company created by the merger of Mylan and Upjohn (Pfizer), focusing on generics and established brands. The forecast for the entire pharmaceutical holding company sector highlights general trends and allows for an assessment of how Viatris's strategy of portfolio optimization and expanding access to medicines fits within the industry context.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20holding&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-holding&v=1772513742758 "Schedule of future (projected) sales of companies in the market segment - Pharma holding")
Future (projected) sales of the market as a whole
Viatris is a global pharmaceutical company specializing in the production of generic and branded medications. Demand for medications is less elastic than for other goods, but the overall economic situation, as reflected here, affects government healthcare budgets and patient purchasing power, which can impact sales volumes and pricing.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513742761 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Viatris Inc.
Viatris, a global pharmaceutical company formed through a merger, demonstrates in this chart its ability to generate profits in the generic and branded drug segments. Efficiency is directly related to scale, which allows for cost reduction, managing a vast drug portfolio, and optimizing the global supply chain.
Market segment marginality - Pharma holding
Viatris is a global pharmaceutical company formed through a merger and focused on the production of generic and brand-name drugs. This indicator reflects the average profitability in the pharmaceutical industry. For Viatris, the key to above-average profitability lies in optimizing its vast product portfolio, manufacturing scale, and expanding into new markets.
Market marginality as a whole
Viatris Inc. was created through a merger to become a global leader in generic and over-the-counter (OTC) medications. This chart shows average profit margins. It illustrates Viatris's low-price, high-volume business model. Profitability in this sector depends on operational efficiency and the ability to compete on price.
Employees in the company, segment and market as a whole
Number of employees in the company Viatris Inc.
Viatris, created by the merger of Mylan and Upjohn (a division of Pfizer), is a global pharmaceutical company. The chart reflects the massive workforce required to produce and distribute a broad portfolio of generic and branded drugs. Workforce dynamics are often linked to business integration, optimization, and restructuring.
Share of the company's employees Viatris Inc. within the market segment - Pharma holding
Viatris, created through the merger of Mylan and a division of Pfizer, is a global pharmaceutical giant specializing primarily in generic and off-patent drugs. This chart demonstrates its massive manufacturing and distribution scale. It reflects the colossal share of pharmacists and factory workers Viatris employs worldwide.
Number of employees in the market segment - Pharma holding
Viatris, created as a result of the merger, is a global pharmaceutical player specializing in generics and well-known brands. This chart illustrates the scale of employment in the pharmaceutical industry, where mergers and acquisitions often lead to staff optimization. The dynamics here reflect trends toward consolidation and the search for efficiency in the industry.
Number of employees in the market as a whole
Viatris, a global pharmaceutical company, produces both generic and branded medications. Employment levels, as reflected in the graph, impact its business through healthcare systems. More employment means more people with health insurance, ensuring stable demand for the affordable medications that form the core of Viatris' portfolio.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Viatris Inc. (VTRS)
Viatris, created by the merger of Mylan and Upjohn, is a giant in the generic and over-the-counter drug market. This chart reflects how the market perceives the performance of its massive global team. The dynamics of the company's market capitalization per employee demonstrate how successfully it is integrating assets and streamlining manufacturing and distribution processes worldwide.
%20of%20the%20company%20Viatris%20Inc.%20(VTRS)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Viatris-Inc.-VTRS&v=1772513742785 "Chart of market capitalization per employee (in thousands of dollars) of the company Viatris Inc. (VTRS)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma holding
Viatris Inc. is a global pharmaceutical company formed by the merger of Mylan and Upjohn (a division of Pfizer). It focuses primarily on generic and brand-name pharmaceuticals with expired patents. This chart shows the industry average cost per employee. It helps understand how the market perceives Viatris's effectiveness in managing its extensive generic drug portfolio and its global manufacturing network.
%20by%20market%20segment%20-%20Pharma%20holding&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-holding&v=1772513742789 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma holding")
Market capitalization per employee (in thousands of dollars) for the overall market
Viatris is a global pharmaceutical company created by the merger of Mylan and Upjohn (a division of Pfizer). The company focuses on producing generic and brand-name medications. This chart provides an overview of how the market views its scalable business model, which combines massive manufacturing and a global distribution network with a corresponding number of employees.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513742813 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Viatris Inc. (VTRS)
Viatris is a global pharmaceutical company created by the merger of Mylan and Upjohn (a division of Pfizer). It specializes in generic and branded off-patent drugs. This chart shows efficiency in the "mass" pharmaceutical business. It measures how efficiently the company manages its vast drug portfolio and large-scale manufacturing to ensure that every employee generates profit.
%20Chart%20Viatris%20Inc.%20(VTRS)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Viatris-Inc.-VTRS&v=1772513742824 "Company Profit Per Employee (in thousands of dollars) Chart Viatris Inc. (VTRS)")
Profit per employee (in thousands of dollars) in the market segment - Pharma holding
Viatris is a generics giant created from Pfizer (Upjohn) and Mylan. This chart shows the benchmark for "Pharm Holdings," but in the generics niche. The average profit per employee here is *lower* than that of "patent" pharma. This is a "commodity" business, where the benchmark is determined by plant efficiency and volume, not R&D.
%20in%20the%20market%20segment%20-%20Pharma%20holding&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-holding&v=1772513742838 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma holding")
Profit per employee (in thousands of dollars) for the market as a whole
Viatris is a global pharmaceutical company created through a merger and focused on the production of generic and brand-name drugs. Its model is based on large-scale manufacturing and distribution. This chart illustrates how operational efficiency at large plants and global reach optimize profit per employee.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513742853 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Viatris Inc. (VTRS)
Viatris, a global pharmaceutical company formed through a merger, uses this metric to assess operational synergies. The chart shows how revenue from a broad portfolio of drugs compares to headcount. An increase in this metric can indicate successful integration and optimization of commercial and manufacturing processes.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Viatris-Inc.-VTRS&v=1772513742872 "Sales chart per company employee Viatris Inc. (VTRS)")
Sales per employee in the market segment - Pharma holding
Viatris was created through a merger and focuses on the production of generic and over-the-counter drugs. In this segment of the pharmaceutical industry, price competition is fierce, making operational efficiency key to success. This chart shows how productive their factories and sales teams are in generating revenue compared to other generic drug manufacturers.
Sales per employee for the market as a whole
Viatris Inc. is a global pharmaceutical company created by the merger of Mylan and Upjohn (a division of Pfizer). This chart shows how much revenue each employee generates in this massive manufacturing and distribution business. It reflects the efficiency of their global manufacturing network and their ability to compete in the low-cost drug market.
Short shares by company, segment and market as a whole
Shares shorted by company Viatris Inc. (VTRS)
Viatris was created through the merger of Mylan and Pfizer's Upjohn division, becoming a giant in generics (drug analogs) and off-patent branded drugs. This chart shows the number of bearish bets. Bearish bets point to persistent pricing pressure in the generics industry and the company's high debt, which hinders its growth and dividend payments.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Viatris-Inc.-VTRS&v=1772513742916 "Short Shares Chart for the Company Viatris Inc. (VTRS)")
Shares shorted by market segment - Pharma holding
Viatris is a global pharmaceutical company created by the merger of Mylan and Upjohn (Pfizer). They focus on generics and off-patent brands. This chart shows overall short positions in the generics sector. High short positions here signal price pressure in the industry or doubts about the ability of companies in the sector to generate growth.
Shares shorted by the overall market
Viatris (VTRS) is a global pharmaceutical giant created from the merger of Mylan and Upjohn (Pfizer). They focus on producing generics and well-known "older" brands. This chart measures the overall level of fear. When pessimism rises, VTRS can look attractive: during a recession, demand for cheaper generics often rises as both patients and healthcare systems economize.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Viatris Inc. (VTRS)
Viatris is a global generics giant (copies of drugs) created by Pfizer and Mylan. **This chart** often shows "oversold" (below 30) due to investor pessimism about sector growth. News of a major asset sale (to pay down debt) can trigger a relief rally, pushing **This chart** out of panic territory.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Viatris-Inc.-VTRS&v=1772513742966 "RSI 14 indicator chart for the company's stock Viatris Inc. (VTRS)")
RSI 14 Market Segment - Pharma holding
Viatris (VTRS) was created through the merger of Pfizer's legacy brands (like Viagra) and the generics giant Mylan. Their businesses boast huge volumes but low margins. This metric measures the "temperature" of the entire pharmaceutical sector. It helps us understand whether VTRS is oversold due to its unique debt load, or whether the entire generics sector has cooled.
RSI 14 for the overall market
Viatris (VTRS) is a global pharmaceutical company formed by the merger of Mylan and Upjohn (a division of Pfizer). They specialize in generics and brand-name drugs. This chart, which shows the overall level of optimism or pessimism, is important for VTRS. During periods of panic, investors may seek refuge in pharmaceuticals, but if the panic is associated with drug pricing pressure, VTRS is at risk.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast VTRS (Viatris Inc.)
Viatris is a global pharmaceutical company created by the merger of Mylan and Upjohn (a division of Pfizer). They specialize in producing generic and off-patent brand-name drugs. This chart is a collective 12-month forecast from analysts. It reflects their expectations for stabilization of generic drug prices and the successful launch of new biosimilars.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-VTRS-Viatris-Inc.&v=1772513743005 "A chart showing analyst consensus forecasts for the expected stock price. VTRS (Viatris Inc.)")
The difference between the consensus estimate and the actual stock price VTRS (Viatris Inc.)
Viatris was created through the merger of Mylan's generics business and Pfizer's legacy brands division (Upjohn). Their core business is selling generic drugs. This chart shows how much analysts believe in their ability to generate cash and find growth opportunities in the low-margin sector. It reflects the gap between the consensus estimate and the current price.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-VTRS-Viatris-Inc.&v=1772513743022 "A chart showing the difference between the consensus forecast and the actual stock price. VTRS (Viatris Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma holding
Viatris (created from Mylan and Upjohn) is a global manufacturer of generics and well-known "legacy" brands (such as Viagra and Lipitor). The company's business is characterized by high volumes and price competition. This chart shows analysts' overall expectations for "big pharma." It reflects whether experts believe the generics market is stable.
Analysts' consensus forecast for the overall market share price
Viatris Inc. is a global manufacturer of generic and branded medications (legacy of Pfizer/Upjohn). Their business is high-volume sales of affordable medications. Market expectations, visible in this chart, influence them. During recessions (pessimism), healthcare systems shift more actively to generics, which could be positive for Viatris.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Viatris Inc.
Viatris is a global pharmaceutical giant created by the merger of Mylan and Upjohn (Pfizer). Their focus is not on R&D, but on the production and sale of generics (analogs) and branded drugs that have lost patent protection (such as Viagra and Lipitor). This chart reflects their high-volume business model: it measures their ability to generate cash flow in the face of pricing pressure.
AKIMA Market Segment Index - Pharma holding
Viatris is a legacy generic company; the company, created by the merger of the legacy businesses of Pfizer (Upjohn) and Mylan, focuses on mass production of generic drugs. This composite metric evaluates companies. The chart shows the sector average. This benchmark: how does Viatris' low-margin, yet scalable, generic model differentiate it from the average pharma company?
The AKIM Index for the overall market
Viatris is a global manufacturer of generics (copycat drugs) and brand-name drugs (like Viagra), formed by the merger of Mylan and Upjohn (Pfizer). It's a low-margin but high-volume business. This chart, which reflects the market average, provides a macro backdrop. It helps assess how Viatris, while dealing with its debt problems, fits into the overall macroeconomic picture.
